A host-centric morphological profiling approach to identify repurposed antiviral drugs.

Elin Asp¹, Jonne Rietdijk², Marianna Tampere¹, Hanna Axelsson³, Duncan Njenda⁴, Swapnil Potdar⁵, Adelinn Kalman¹, Polina Georgieva², Maris Lapins², Flavio Ballante³, Alicia Soler⁶, Martin de Kort⁶, Tero Aittokallio^5,7,8, Andrea Zaliani⁹, Maria Kuzikov⁹, Philip Gribbon⁹, Donald Lo⁶, Jordi Carreras-Puigvert², Brinton Seashore-Ludlow^1,3, Ola Spjuth², Päivi Östling¹

¹Department of Oncology and Pathology and Science for Life Laboratory, Karolinska Institutet, 171 76 Stockholm, Sweden.

²Department of Pharmaceutical Biosciences and Science for Life Laboratory, Uppsala University, 75124 Uppsala, Sweden.

³Chemical Biology Consortium Sweden (CBCS), Science for Life Laboratory, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, 17176 Stockholm, Sweden.

⁴Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, 17176 Stockholm, Sweden.

⁵Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland.

⁶European Infrastructure for Translational Medicine (EATRIS ERIC), Amsterdam, the Netherlands.

⁷Institute of Cancer Research, Department of Cancer Genetics, Oslo University Hospital, Oslo, Norway.

⁸Oslo Centre for Biostatistics and Epidemiology (OCBE), Faculty of Medicine, University of Oslo, Oslo, Norway.

⁹Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP), 22525 Hamburg, Germany.

PubMed PMC DOI PDF

Abstract

Antiviral drug discovery has traditionally targeted viral proteins, while host-directed strategies remain underexplored. We present a systematic drug repurposing strategy that uses morphological profiling to identify host-targeting antivirals. Using cell painting, we demonstrate that SARS-CoV-2 infection can be accurately determined from the morphological profile of virus-infected cells. Moreover,…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.